Ajay Jayant Kirtane

Ajay Jayant Kirtane

Auto-generated profile, based on publicly available information

Ajay Jayant Kirtane

Columbia University Medical Center

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2016 in Circulation
Verified
Journal Article
Closed access
AKAjay J. Kirtane
Ajay J. Kirtane
DDDarshan Doshi
Darshan Doshi
MLMartin B. Leon
Martin B. Leon
JLJohn M. Lasala
John M. Lasala
EOE. Magnus Ohman
E. Magnus Ohman
JMJeffrey W. Moses
Jeffrey W. Moses
Patients with severe coronary artery disease with a clinical indication for revascularization but who are at high procedural risk because of patient comorbidities, complexity of coronary anatomy, and/or poor hemodynamics represent an understudied and potentially underserved patient population. Through advances in percutaneous interventional techniques and technologies and improvements in patient selection, current percutaneous coronary intervention may allow appropriate patients to benefit safely from revascularization procedures that might not have been offered in the past. The burgeoning interest in these procedures in some respects reflects an evolutionary step within the field of percutaneous coronary intervention. However, because of the clinical complexity of many of these patients and procedures, it is critical to develop dedicated specialists within interventional cardiology who are trained with the cognitive and technical skills to select these patients appropriately and to perform these procedures safely. Preprocedural issues such as multidisciplinary risk and treatment assessments are highly relevant to the successful treatment of these patients, and knowledge gaps and future directions to improve outcomes in this emerging area are discussed. Ultimately, an evolution of contemporary interventional cardiology is necessary to treat the increasingly higher-risk patients with whom we are confronted.

6 February 2023 in JACC
Verified
Journal Article
Closed access
ATAlexander G Truesdell
Alexander G Truesdell
MAMirvat A Alasnag
Mirvat A Alasnag
PKPrashant Kaul
Prashant Kaul
SRSyed Tanveer Rab
Syed Tanveer Rab
RRRobert F Riley
Robert F Riley
ACAcc Interventional Council
Acc Interventional Council

1 October 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MZMingyou Zhang
Mingyou Zhang
MMMitsuaki Matsumura
Mitsuaki Matsumura
EUEisuke Usui
Eisuke Usui
MNMasahiko Noguchi
Masahiko Noguchi
TFTatsuhiro Fujimura
Tatsuhiro Fujimura
AMAkiko Maehara
Akiko Maehara
Background: Coronary calcification inhibits stent expansion. We sought to establish an intravascular ultrasound–derived calcium score to predict stent underexpansion. Methods: This is a retrospective observational study including de novo lesions that underwent intravascular ultrasound–guided stenting and had maximum superficial calcium angle >270°. Lesions with angiographic calcium not treated with atherectomy or scoring/cutting balloon before stent implantation were randomly divided into derivation and validation cohorts. The end point was stent expansion (minimum stent area/average of reference lumen area) at the maximum calcium site, and stent expansion 270° longer than 5 mm (regression coefficient, −13.0 [95% CI, −18.1 to −7.8], P <0.0001), (2) 360° of superficial calcium (regression coefficient, −14.2 [95% CI, −22.8 to −5.5], P =0.001), (3) calcified nodule (regression coefficient, −8.3 [95% CI, −14.3 to −2.2], P =0.007), and (4) vessel diameter <3.5 mm (regression coefficient, −9.4 [95% CI, −16.0 to −2.7], P =0.006). The calcium score (0-4) was significantly correlated with poor stent expansion (regression coefficient, −8.1 [95% CI, −10.5 to −5.7], P <0.0001) in the validation cohort as well as in the atherectomy cohort (regression coefficient, −4.8 [95% CI, −7.2 to −2.5], P <0.0001) with significant interaction between validation and atherectomy cohorts ( P interaction =0.02). In lesions without angiographic calcium, all calcium severity parameters were less than in the validation cohort, and stent underexpansion was observed in only 1.5% (1/67) of lesions. Conclusions: This intravascular ultrasound calcium score provides the interventionalists with a reliable tool to identify calcified stenoses at risk for stent underexpansion and requiring adjunctive calcium modification before stent implantation.

2 March 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
YAYousif Ahmad
Yousif Ahmad
JHJames P Howard
James P Howard
AAAhran D Arnold
Ahran D Arnold
CCChristopher M Cook
Christopher M Cook
MPMegha Prasad
Megha Prasad
DKDimitri Karmpaliotis
Dimitri Karmpaliotis
The optimal method of revascularization for patients with left main coronary artery disease (LMCAD) is controversial. Coronary artery bypass graft surgery (CABG) has traditionally been considered the gold standard therapy, and recent randomized trials comparing CABG with percutaneous coronary intervention (PCI) with drug-eluting stents (DES) have reported conflicting outcomes. We, therefore, performed a systematic review and updated meta-analysis comparing CABG to PCI with DES for the treatment of LMCAD. We systematically identified all randomized trials comparing PCI with DES vs. CABG in patients with LMCAD. The primary efficacy endpoint was all-cause mortality. Secondary endpoints included cardiac death, myocardial infarction (MI), stroke, and unplanned revascularization. All analyses were by intention-to-treat. There were five eligible trials in which 4612 patients were randomized. The weighted mean follow-up duration was 67.1 months. There were no significant differences between PCI and CABG for the risk of all-cause mortality [relative risk (RR) 1.03, 95% confidence interval (CI) 0.81–1.32; P = 0.779] or cardiac death (RR 1.03, 95% CI 0.79–1.34; P = 0.817). There were also no significant differences in the risk of stroke (RR 0.74, 95% CI 0.35–1.50; P = 0.400) or MI (RR 1.22, 95% CI 0.96–1.56; P = 0.110). Percutaneous coronary intervention was associated with an increased risk of unplanned revascularization (RR 1.73, 95% CI 1.49–2.02; P < 0.001). The totality of randomized clinical trial evidence demonstrated similar long-term mortality after PCI with DES compared with CABG in patients with LMCAD. Nor were there significant differences in cardiac death, stroke, or MI between PCI and CABG. Unplanned revascularization procedures were less common after CABG compared with PCI. These findings may inform clinical decision-making between cardiologists, surgeons, and patients with LMCAD.

25 March 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
FMFelix Mahfoud
Felix Mahfoud
MAMichel Azizi
Michel Azizi
SESebastian Ewen
Sebastian Ewen
APAtul Pathak
Atul Pathak
CUChristian Ukena
Christian Ukena
WWWilliam Wijns
William Wijns
Device-based hypertension treatment is a complementary and possibly alternative approach to conventional lifestyle changes combined with antihypertensive medications to achieve and maintain optimal blood pressure (BP) control. A series of clinical trials assessing novel technologies are currently ongoing for device-based hypertension treatment, including endovascular catheter-based renal denervation (RDN), baroreceptor activation therapy, endovascular baroreflex amplification, and cardiac pacemaker-mediated hypertension treatment.

1 August 2016 in JACC
Verified
Journal Article
Closed access
DDDarshan Doshi
Darshan Doshi
OBOri Ben-Yehuda
Ori Ben-Yehuda
MBMachaon Bonafede
Machaon Bonafede
NJNoam Josephy
Noam Josephy
DKDimitri Karmpaliotis
Dimitri Karmpaliotis
AKAjay J. Kirtane
Ajay J. Kirtane